Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.
D000218:Adamantane / Q000031:analogs & derivatives*; D000284:Administration, Oral; D000328:Adult; D001831:Body Temperature; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype; D009980:Influenza A virus / Q000187:drug effects*; D007251:Influenza, Human / Q000188:drug therapy*; D008297:Male; D009297:Nasal Mucosa / Q000382:microbiology; D011897:Random Allocation; D012299:Rimantadine / Q000008:administration & dosage / Q000627:therapeutic use*
D012299:Rimantadine; D000218:Adamantane